Advanced Search
Contact | Corporate | Help

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Sponsors:
  • Sanofi-Aventis
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Non-small Cell Lung Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: docetaxel; oxaliplatin; bevacizumab
Enrollment:
53

Additional information about NCT00356122.


SourceSolution © 2008-2012